AlphAIalphai — Financial news for AI agents
manilatimes.netJUN 21 min read$PHAR

Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York

Pharming Group said its CEO, Fabrice Chouraqui, will take part in a fireside chat Q&A at the 2026 Jefferies Global Healthcare Conference in New York on June 4 at 11:05am EDT/17:05 CEST. The company will provide a live webcast and replay on its website. The event runs June 3-4, 2026.

Original reporting
manilatimes.net
Published Jun 2, 2026, 7:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 7:50 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York — source image
Source · manilatimes.net
Decision brief

The 30-second read

$PHARNeutralLow
01

Why it matters

No new company-specific catalysts are disclosed; the main trading relevance is the potential for future incremental disclosures during/after the event.

02

Market read

Pre-event visibility for PHAR; actionable only if subsequent Q&A/webcast reveals new material information.

03

What to watch

Traders should treat this as a scheduling note and only re-rate impact after the webcast if new data or Q&A disclosures emerge.

Relevance 5/10Novelty 2/10Timing: Ahead of June 4 fireside chat (11:05am EDT)

Background

The article is a corporate announcement that Pharming will participate in the Jefferies Global Healthcare Conference and host a CEO fireside chat with webcast/replay availability.

Company-level read

Ticker impact

$PHARNeutralHigh confidence
Context

Pharming Group is the named company announcing CEO Fabrice Chouraqui’s fireside chat at the Jefferies Global Healthcare Conference on June 4.

Expected impact

Low likelihood of a material, immediate price move; any impact would come only if the fireside chat later reveals new information.

Evidence & confidence

The release only schedules participation and webcast details; it does not provide results, guidance, regulatory actions, or transactions.

Market effects

Sector

Minimal; conference participation is common across biotech and does not, by itself, change sector fundamentals.

Regional

Minimal; event is US-based but does not cite US-specific regulatory or commercial developments.

Global

Minimal; no new global product, trial, or partnership information is provided.

Counterpoint

What could challenge this read

If the fireside chat includes unexpected trial updates or guidance, the market reaction could be sharper than this pre-event notice suggests.

Key entities

  • company
    Pharming Group N.V.

    Subject of the announcement; CEO will participate in a June 4 fireside chat at the Jefferies Global Healthcare Conference.

  • person
    Fabrice Chouraqui

    CEO scheduled to participate in the fireside chat Q&A session.

  • event
    Jefferies Global Healthcare Conference

    Investor conference in New York where management will present and take Q&A.

Read at source← All news

Related articles

JUL 30
$PHARMedAI 8/10

Pharming Group N.V.: Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader ther

Pharming Group N.V. reported Q2 2026 total revenues of US$90.2m, down 3% year over year. RUCONEST revenue was US$72.3m, down 10% YoY, while Joenja (leniolisib) revenue rose to US$17.9m, up 40% YoY. Q2 operating profit fell to US$1.3m. The company revised 2026 revenue guidance to US$375m-395m and operating expense guidance to US$315m-320m.

finanznachrichten.de7 min
JUN 4
$PHARMedAI 9/10

Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS

Pharming said the U.S. FDA accepted its resubmitted supplemental NDA for Joenja (leniolisib) to treat children ages 4–11 with APDS. After a Jan. 30, 2026 CRL and a March 26 Type A meeting, the sNDA seeks approval for 40 mg and 50 mg twice daily for patients ≥27 kg, with FDA requesting additional batch-testing analytical data. The PDUFA target action date is Oct. 24, 2026. A separate sNDA for lower-weight patients is planned for the second half of 2026.

manilatimes.net4 min
AUG 11
$PMed

Everpure Lands New Design Win with Second Top-Five Hyperscaler

Everpure (NYSE: P) said it secured a design win and supply agreement with a second top-five hyperscaler, building on a similar win announced in late 2024. The company attributes the deal to its DirectFlash technology for hyperscale storage. Everpure expects revenue contributions starting in fiscal 2028 and beyond.

itwire.com2 min
AUG 11
$LNTMedAI 8/10

ONGC awards offshore contracts to L&T Energy Hydrocarbon Offshore

Larsen & Toubro’s subsidiary L&T Energy Hydrocarbon Offshore (LTEH Offshore) won offshore contracts from Oil & Natural Gas Corporation (ONGC) for India’s western coast. The awards cover ONGC’s Pipeline Replacement Project (PRP-X) and construction of four wellhead platforms. L&T said combined contract value is INR 50-100 billion (about $525.2m-$1.05b).

bgnes.com3 min